$0.87 +0.01 (1.63%) Galectin Therapeutics Inc - NASDAQ

Dec. 2, 2016 | 12:44 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 0.87
Trade Time: Dec 02 12:44 PM Eastern Daylight Time
Change: +0.01 (1.63%)
Prev Close: 0.86
Open: 0.87
Bid: 0.86
Ask: 0.89
  1. 5 Biotech Stocks to Watch as Interest in NASH Increases

    TalkMarkets | Sep. 22, 2016 | 13:45PM EST
  2. Morning Market Losers

    Benzinga | Nov. 20, 2015 | 10:06AM EST
  3. Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference

    Benzinga | Oct. 7, 2015 | 15:09PM EST
  4. Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz ...

    GuruFocus | Oct. 6, 2015 | 23:03PM EST
  5. Benzinga's Top Initiations

    Benzinga | Sep. 21, 2015 | 09:11AM EST
  6. Galectin Therapeutics Announces Start of Phase 2 Clinical Trial with GR-MD-02 in NASH with Advanced Fibrosis

    Benzinga | Sep. 16, 2015 | 06:58AM EST
  7. Mid-Day Market Update: Thursday's Movers, China, Tesla And More

    Benzinga | Aug. 13, 2015 | 12:09PM EST
  8. Morning Market Gainers

    Benzinga | Aug. 13, 2015 | 08:45AM EST
  9. Morning Market Gainers

    Benzinga | Jan. 7, 2015 | 09:38AM EST
  10. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 24, 2014 | 10:12AM EST
  11. MLV & Co Has Positive Outlook On Galectin Therapeutics Inc

    Benzinga | Sep. 16, 2014 | 08:56AM EST
  12. UPDATE: Aegis Capital Downgrades Galectin Therapeutics

    Benzinga | Aug. 1, 2014 | 11:26AM EST
  13. Galectin Issues Statement on Yesterday's Sell Off, Says Attributed To Negative Social Media Posts and Misinterpretation

    Benzinga | Jul. 30, 2014 | 08:09AM EST
  14. Morning Market Losers

    Benzinga | Jul. 29, 2014 | 08:54AM EST
  15. Galectin Offers Results in Preclinical Model of GR-MD-02, Results Show Significant Disease Improvement

    Benzinga | Jun. 23, 2014 | 07:06AM EST
Trading Center